Details for New Drug Application (NDA): 217785
✉ Email this page to a colleague
The generic ingredient in REZDIFFRA is resmetirom. One supplier is listed for this compound. Additional details are available on the resmetirom profile page.
Summary for 217785
Tradename: | REZDIFFRA |
Applicant: | Madrigal |
Ingredient: | resmetirom |
Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217785
Generic Entry Date for 217785*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 217785
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
REZDIFFRA | resmetirom | TABLET;ORAL | 217785 | NDA | Madrigal Pharmaceuticals, Inc. | 82576-060 | 82576-060-30 | 30 TABLET, COATED in 1 BOTTLE (82576-060-30) |
REZDIFFRA | resmetirom | TABLET;ORAL | 217785 | NDA | Madrigal Pharmaceuticals, Inc. | 82576-080 | 82576-080-30 | 30 TABLET, COATED in 1 BOTTLE (82576-080-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 60MG | ||||
Approval Date: | Mar 14, 2024 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Mar 14, 2029 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 17, 2033 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 17, 2033 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) |
Complete Access Available with Subscription